secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001558370-23-007978
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q1 net loss $3.1M on revenue decline; positive CHMP opinion for PRX-102
--------------------------------------------------------------------------------

- Revenue from goods fell 43% to $5.1M; license and R&D revenue down 37% to $4.5M.
- Net loss of $3.1M ($0.05/sh) vs $2.3M loss in Q1 2022; cash $33.0M.
- Feb 24, 2023: CHMP positive opinion recommending EU approval of PRX-102 for Fabry disease.
- First patient dosed in Phase I trial of PRX-115 (PEGylated uricase) for severe gout.
- Voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/0001558370-23-007978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/plx-20230504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer